Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Clarityn
|
| gptkbp:appointed_by |
oral tablet
oral solution |
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:brand |
gptkb:Clarinex
|
| gptkbp:category |
Category C
|
| gptkbp:class |
second-generation antihistamine
|
| gptkbp:clinical_trial |
Phase IV
Phase III seasonal allergies skin allergies year-round allergies |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to desloratadine |
| gptkbp:dosage_form |
5 mg once daily
1 mg for children 2-5 years old 2.5 mg for children 6-11 years old |
| gptkbp:formulation |
gptkb:product
gptkb:item tablets orally disintegrating tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Clarinex
|
| gptkbp:ingredients |
desloratadine
|
| gptkbp:interacts_with |
gptkb:beer
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:is_available_in |
liquid form
tablet form |
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_used_for |
allergic rhinitis
chronic idiopathic urticaria |
| gptkbp:lifespan |
27 hours
|
| gptkbp:manufacturer |
gptkb:Schering-Plough
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
desloratadine
|
| gptkbp:related_to |
gptkb:Claritin
gptkb:loratadine |
| gptkbp:side_effect |
dizziness
fatigue headache nausea sore throat rash insomnia dry mouth anaphylaxis palpitations |
| gptkbp:storage |
room temperature
dry place protected from light |